25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 Capital

Key Points

• 111 Capital has established a new position in Sarepta Therapeutics, acquiring 25,360 shares valued at approximately $434,000.
• Sarepta Therapeutics reported significant earnings, with a 68.4% increase in revenue year-over-year, totaling $611.09 million, and earnings per share of $2.02 which exceeded analysts' expectations.
• Analysts have mixed views on Sarepta, with a consensus rating of "Hold" and a target price of $39.32, while Wells Fargo and BMO Capital have upgraded their price objectives for the stock.

111 Capital bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 25,360 shares of the biotechnology company's stock, valued at approximately $434,000.

Other large investors have also recently added to or reduced their stakes in the company. Byrne Asset Management LLC bought a new position in Sarepta Therapeutics during the 1st quarter worth about $30,000. Center for Financial Planning Inc. bought a new position in Sarepta Therapeutics during the 1st quarter worth about $31,000. Ancora Advisors LLC increased its holdings in Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA bought a new position in Sarepta Therapeutics during the 1st quarter worth about $44,000. Finally, Pandora Wealth Inc. bought a new position in Sarepta Therapeutics during the 1st quarter worth about $45,000. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Up 1.3%

Sarepta Therapeutics stock opened at $22.64 on Monday. The stock has a market cap of $2.21 billion, a P/E ratio of -26.02 and a beta of 0.51. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $138.81. The company's 50-day moving average price is $18.39 and its two-hundred day moving average price is $32.22.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. During the same period in the prior year, the firm earned $0.07 EPS. The business's revenue was up 68.4% on a year-over-year basis. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on SRPT shares. Royal Bank Of Canada lowered their target price on Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating for the company in a report on Thursday, July 17th. UBS Group restated a "neutral" rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Wells Fargo & Company increased their price objective on shares of Sarepta Therapeutics from $48.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. BMO Capital Markets upgraded shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and set a $50.00 price objective for the company in a research note on Monday, September 22nd. Finally, Jefferies Financial Group reduced their price objective on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating for the company in a research note on Thursday, July 24th. Nine investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and seven have assigned a Sell rating to the company's stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of "Hold" and a consensus target price of $39.32.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.